GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is 45.88.
| Share Price | ₹2,214.1 | Jun 19,2026 |
| Market Cap | ₹62,480.5 Cr | |
| Earnings-TTM | ₹1,362.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 45.88x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹62,480.5 Cr] as on Jun 19,2026
(/) Earnings [ ₹1,362.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 45.88x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay 45.88 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 22.48x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.51x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 1,361.95 | 45.88 | 62,480.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 38.12 | 440,794.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 69.69 | 178,956.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 70.07 | 149,820.0 |
| CIPLA LTD | 3,869.79 | 28.26 | 109,370.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.61 | 106,133.0 |
| MANKIND PHARMA LTD | 1,926.41 | 51.82 | 99,835.6 |
| LUPIN LTD | 5,355.47 | 20.08 | 107,537.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 21.44 | 107,758.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 24.61 | 86,183.0 |
| LAURUS LABS LTD | 889.85 | 85.77 | 76,323.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 20.08x |
| Max industry PE | 85.77x |
| Median industry PE | 38.12x |
| Average industry PE | 43.76x |
You may also like the below Video Courses